| |
| Target Portfolio >>Unment Needs |
| The unmet need for autoimmune therapies
is very large |
- ~20 million Americans suffer from over 80 different autoimmune diseases, including:
- multiple sclerosis
- psoriasis
- rheumatoid arthritis
- type-1 diabetes mellitus
- Current treatments are inadequate.
- The challenge for drug discovery has been the need to suppress or delete the disease-causing autoreactive T cells without compromising the ability of the remainder of the immune system to protect against infections or cancers.
- The commercial opportunities are enormous
- Example: the four leading MS treatments – all injectables – generated over $4 billion in revenues last year.
|
|
|
 |
|
| February 2011 |
| February 2011 AIRMID partners with Circassia to develop topical PAP-1 |
|
| January 2010 |
| Joe Sum joins
AIRMID Board of Directors |
| July 2009 |
AIRMID partners with Kineta
to develop ShK peptides
|
|
more... |
|
